In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.
When discussing GLP-1 receptor agonists for patients with type 2 diabetes, it is important to know which adverse events may occur and which are myths.
For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.
Read which GLP-1 RA I favor for patients with type 2 diabetes who are overweight or obese.
How I use an oral GLP-1RA in the clinic.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.